Drug Trial Radar · NCT00599521
Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%
Last checked: Nov 19, 2026Latest source record: Feb 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,067
Actual
Start
Nov 2007
Primary completion
Nov 2008
Study completion Dec 2008
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Jan 23, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether Adapalene, 0.1% is safe and effective in the treatment of Acne Vulgaris.
Conditions
- Acne Vulgaris
Interventions
Adapalene lotion 0.1%Drug
Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
Adapalene Lotion VehicleDrug
Vehicle will be applied topically to the face, once a day, for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Co-Primary Endpoint: Success Rate on Investigator's Global Assessment (IGA) From Baseline to Week 12Time frame: From Baseline to Week 12
- Co-Primary Endpoint: Absolute Change in Total Lesion Counts From Baseline to Week 12Time frame: Baseline to 12 weeks
- Co-Primary Endpoint: Absolute Change in Inflammatory Lesion Count From Baseline to Week 12Time frame: Baseline to Week 12
- Co-Primary Endpoint: Absolute Change in NonInflammatory Lesion Counts From Baseline to Week 12Time frame: Baseline to Week 12
Locations
34 sites in 2 countries. Site status is shown where the registry gives one.
University of California
San Diego, California
Dermatology Specialists, Inc.
Vista, California
Cherry Creek Dermatology
Denver, Colorado
Advanced Dermatology and Cosmetic Surgery
Ormond Beach, Florida
Dermatology Research
Pinellas Park, Florida
Christie Clinic, PC
Champaign, Illinois
Compliant Clinical Research
Olathe, Kansas
Dermatology Specialists
Louisville, Kentucky
East Coast Clinical Research, Inc.
Haverhill, Massachusetts
Midwest Cutaneous Research
Clinton Township, Michigan
Henry Ford Medical Center-Dept. of Dermatology
Detroit, Michigan
Minnesota Clinical Study Centert
Fridley, Minnesota
Skin Specialists, PC
Omaha, Nebraska
Cindy Lamerson
Reno, Nevada
Fran Cook-Bolden
New York, New York
Dermatology Associates of Rochester
Rochester, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Wake Research Associates, LLC
Raleigh, North Carolina
University Dermatology Consultants
Cincinnati, Ohio
Central Sooner Research
Norman, Oklahoma
Northwest Cutaneous Research Specialists
Portland, Oregon
Palmetto Medical Research
Mt. Pleasant, South Carolina
Dermatology Associates
Knoxville, Tennessee
Dermatology Research Associates
Nashville, Tennessee
Tennessee Clinical Research Center
Nashville, Tennessee
J&S Studies, Inc.
Bryan, Texas
The Center for Skin Research
Houston, Texas
Dermatology Research Center
Salt Lake City, Utah
Premier Clinical Research
Spokane, Washington
Dermatology Associates
Calgary, Alberta, Canada
Derm Research @ 888 Inc
Vancouver, British Columbia, Canada
Ultranova Skincare
Barrie, Ontario, Canada
North Bay Dermatology Centre
North Bay, Ontario, Canada
Siena Medical Research
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.